GET DAILY SIGNALSCapricor Therapeutics (CAPR) Q3 2026 Earnings: Regulatory Path Remains the Focus
Key Takeaways
- Capricor Therapeutics (NASDAQ: CAPR) is expected to report results for its third quarter ended September 30, 2026, with the exact date still to be confirmed by the company.
- The company remains pre-revenue, with analyst forecasts showing a wide range that reflects uncertainty around the timing of a potential commercial launch of its lead therapy, deramiocel.
- Investors will be watching closely for updates on the amended Biologics License Application (BLA) — the formal request for U.S. marketing approval — for deramiocel in Duchenne muscular dystrophy (DMD).
- Capricor's most recent quarter (Q2 2026) showed a wider-than-expected net loss of roughly $40.7 million, driven by higher research and development (R&D) and general and administrative (G&A) spending.
- Regulatory progress, cash runway, and pre-commercialization spending are expected to matter more to the stock than the headline loss figure.
- You can find more details about this ticker's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
- Explore Trending AI Robots to discover automated trading strategies currently drawing attention in the market.
Earnings Context and Why It Matters
Capricor Therapeutics is a clinical-stage biotechnology company developing cell and exosome-based therapies, with its lead candidate deramiocel aimed at treating the cardiac complications of Duchenne muscular dystrophy. Because the company has not yet begun generating product revenue, its quarterly results are less about the bottom line and more about regulatory progress, spending discipline, and the strength of its balance sheet. This report arrives at a pivotal moment: the U.S. Food and Drug Administration (FDA) has agreed to review an amended application focused on an upper-limb indication, and investors are eager for clarity on the approval timeline. For shareholders, the earnings event doubles as a progress check on a potentially transformative commercial launch.
Earnings Expectations
Because CAPR is pre-commercial and has reported zero product revenue in recent quarters, consensus estimates for the third quarter remain highly uncertain and vary considerably across sources. Widely cited forecasts put the quarterly loss per share at roughly $0.13, though individual estimates range from about $0.13 to $0.44 per share, reflecting limited visibility into spending and launch timing. Revenue expectations are similarly spread, spanning from approximately $10 million to more than $41 million depending on whether analysts model any early milestone or collaboration-related income.
For context, Capricor posted a net loss of $0.54 per share in the third quarter of 2025. In the most recent quarter (Q2 2026), the company reported a loss of $0.70 per share, wider than consensus, alongside roughly $237.9 million in cash and cash equivalents. Historically, the stock has reacted more sharply to regulatory and clinical news than to the headline earnings figure, and this quarter is likely to follow that pattern. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Sentiment heading into this report is heavily influenced by regulatory developments rather than quarterly financials. In August 2026, CAPR shares surged sharply in after-hours trading after the company disclosed that the FDA had agreed to review its amended BLA for deramiocel focused on an upper-limb indication, with an extension of the PDUFA (Prescription Drug User Fee Act) goal date expected. That news reset investor expectations around the approval pathway, even as the stock has since experienced meaningful volatility.
Key risk factors to watch include the timing and outcome of the FDA review, the pace of pre-commercialization spending, and any updates on the company's manufacturing readiness. A wider-than-expected loss could weigh on shares, but regulatory commentary on the call is likely to be the dominant driver of the market's reaction.
Forward Outlook and Key Factors to Monitor
Looking beyond the quarterly numbers, investors should focus on the regulatory pathway for deramiocel. The most important catalyst is the amended BLA review and the expected PDUFA goal-date extension, which will shape the timeline for a potential U.S. launch. Any additional clarity from the FDA — including requests for further data or the scheduling of an advisory committee meeting — could move the stock in either direction.
Manufacturing and commercial readiness are also central. Capricor has said its San Diego facility is operational for a potential launch, with full expansion validation expected in 2027. Watch for updates on capacity, supply agreements, and progress with its commercial partner as the company transitions toward potential commercialization.
Finally, monitor spending and the balance sheet. The company ended its last quarter with roughly $237.9 million in cash, but rising R&D and G&A costs, including legal expenses tied to its partnership dispute and pre-launch initiatives, will determine how far that runway stretches. Cost discipline and any revenue or collaboration milestone recognition will be important signals in the quarters ahead. From what I see, AI-driven signals can help track these developments more efficiently.
Enhancing Analysis with AI Tools
In my own research process, I frequently rely on Tickeron’s AI Screener to filter biotech names and compare technical and fundamental metrics across peers. This tool helps surface relevant patterns and momentum shifts without replacing deeper fundamental review. It has become a practical part of how I prepare for events like upcoming earnings and regulatory updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CAPR in upward trend: price rose above 50-day moving average on November 03, 2026
CAPR moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 38 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on CAPR as a result. In 69 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for CAPR just turned positive on October 29, 2026. Looking at past instances where CAPR's MACD turned positive, the stock continued to rise in 35 of 42 cases over the following month. The odds of a continued upward trend are 83%.
Following a +14.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAPR advanced for three days, in 232 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for CAPR crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
CAPR broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CAPR entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. CAPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.125) is normal, around the industry mean (3.498). P/E Ratio (-3.673) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (7.610) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (125.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Develops innovative products for the treatment of cardiovascular diseases
Industry Biotechnology
Advertisement